Safety of regular formoterol or salmeterol in adults with asthma: An overview of Cochrane reviews

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Cates, Christopher J ^a   Wieland, L Susan ^b   Oleszczuk, Marta ^c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL; PLACEBO; SALMETEROL;

ADULT; ADVERSE EVENT; ALL CAUSE MORTALITY; ARTICLE; ASTHMA; DISEASE SEVERITY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84938835112     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010314     Document Type: Article

References (27)

1. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
2. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-19. [1474-547X: (Electronic)]
3. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al.Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal 2008;31(1):143-78.
4. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. American Review of Respiratory Disease 1980;121(2):389-413. [: (Print)]
5. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77. [0277-6715: (Print)]
6. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034-7.
7. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2; : CD006363]
8. Cates CJ. Safety of tiotropium. BMJ 2011;342:d2970.
9. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005; : CD010005]
10. Chan A-W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
11. Chan A-W, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 2004;171(7):735-40.
12. Cockcroft D. Airway hyper-responsiveness as a determinant of the early asthmatic response to inhaled allergen. Journal of Asthma 2006;43(3):175-8.
13. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437-43. [0098-7484: (Print)]
14. Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al.CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8.
15. Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al.Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Canadian Respiratory Journal 2010;17(2):57-8.
16. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128(5):e1147-54.
17. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
18. Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta-2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. Journal of Allergy and Clinical Immunology 1990;85(4):755-62.
19. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
20. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-12.
21. Senn SJ, Lillienthal J, Patalano F, Till D. An incomplete blocks cross-over in asthma: a case study in collaboration. In: Vollmar J, Hothorn LA editor(s). Cross-over Clinical Trials. Stuttgart: Fischer, 1997:3-26.
22. Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10]
23. Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 (revised 2012).
24. Tattersfield AE. Current issues with beta2-adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology 2006;31(2-3):107-18.
25. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996;9(8):1684-8.
26. Weinberger M, Abu-Hasan M. Life threatening asthma during treatment with salmeterol. New England Journal of Medicine 2006;355:852-3.
27. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5.